FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

DRUG3 trials

Sponsors

Merck KGaA, Darmstadt, Germany, University of Campania Luigi Vanvitelli, Luye Pharma Group Ltd.

Conditions

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal CancerMetastatic Colorectal Cancer (mCRC)

Phase 1

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Not yet recruitingNCT07391566

Luye Pharma Group Ltd.Metastatic Colorectal Cancer (mCRC)

Start: 2026-03-31End: 2028-12-31Target: 99Updated: 2026-02-06

Phase 3

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

CompletedNCT00154102

Merck KGaA, Darmstadt, GermanyEpidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Start: 2004-05-31End: 2011-03-31Updated: 2017-01-30

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

RecruitingNCT07389265

University of Campania Luigi VanvitelliMetastatic Colorectal Cancer (mCRC)

Start: 2025-10-01End: 2030-10-01Target: 480Updated: 2026-02-05

Related Papers

Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.

2021-11-1754 citations

The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy.

Journal of Clinical Oncology2020-02-01

Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm.

2017-11-0119 citations

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

JAMA Oncology2016-10-10708 citations

Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.

Journal of Clinical Oncology2016-02-017 citations

Treatment outcome according to tumor <i>RAS</i> mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.

Journal of Clinical Oncology2014-05-2035 citations

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

2012-12-19117 citations

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

2009-04-012738 citations